menu
    • menu

    Company profile for Glaukos

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—...
    Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GlaukosUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    229 Avenida Fabricante, San Clemente, CA 92653
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glaukos.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glaukos to Participate in J.P. Morgan Healthcare Conference
    Glaukos to Participate in J.P. Morgan Healthcare Conference

    16 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251216607694/en/Glaukos-Announces-Participation-in-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    16 Dec 2025
    Share Share
    Glaukos Announces Participation In Upcoming Investor Conferences
    Glaukos Announces Participation In Upcoming Investor Conferences

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103102041/en/Glaukos-Announces-Participation-in-Upcoming-Investor-Conferences

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Glaukos Announces Third Quarter 2025 Financial Results
    Glaukos Announces Third Quarter 2025 Financial Results

    29 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251029588082/en/Glaukos-Announces-Third-Quarter-2025-Financial-Results

    BUSINESSWIRE
    29 Oct 2025
    Share Share
    Glaukos Announces FDA Approval Of Epioxa
    Glaukos Announces FDA Approval Of Epioxa

    20 Oct 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251020818094/en/Glaukos-Announces-FDA-Approval-of-Epioxa

    BUSINESS WIRE
    20 Oct 2025
    Share Share
    Glaukos’s Epioxa Receives Approval in US
    Glaukos’s Epioxa Receives Approval in US

    17 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219910

    FDA
    17 Oct 2025
    Share Share
    Glaukos’s Epioxa HD Receives Approval in US
    Glaukos’s Epioxa HD Receives Approval in US

    17 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219910

    FDA
    17 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search